These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 26884069

  • 1. UHRF1 overexpression is involved in cell proliferation and biochemical recurrence in prostate cancer after radical prostatectomy.
    Wan X, Yang S, Huang W, Wu D, Chen H, Wu M, Li J, Li T, Li Y.
    J Exp Clin Cancer Res; 2016 Feb 17; 35():34. PubMed ID: 26884069
    [Abstract] [Full Text] [Related]

  • 2. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
    Jiao L, Shen D, Liu G, Jia J, Geng J, Wang H, Sun Y.
    Anticancer Res; 2014 Jun 17; 34(6):2919-25. PubMed ID: 24922655
    [Abstract] [Full Text] [Related]

  • 3. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression.
    Babbio F, Pistore C, Curti L, Castiglioni I, Kunderfranco P, Brino L, Oudet P, Seiler R, Thalman GN, Roggero E, Sarti M, Pinton S, Mello-Grand M, Chiorino G, Catapano CV, Carbone GM, Bonapace IM.
    Oncogene; 2012 Nov 15; 31(46):4878-87. PubMed ID: 22330138
    [Abstract] [Full Text] [Related]

  • 4. miR-196a-mediated downregulation of p27kip1 protein promotes prostate cancer proliferation and relates to biochemical recurrence after radical prostatectomy.
    Zhan B, Huang L, Chen Y, Ye W, Li J, Chen J, Yang S, Jiang W.
    Prostate; 2020 Sep 15; 80(12):1024-1037. PubMed ID: 32628792
    [Abstract] [Full Text] [Related]

  • 5. Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.
    Yu L, Toriseva M, Tuomala M, Seikkula H, Elo T, Tuomela J, Kallajoki M, Mirtti T, Taimen P, Boström PJ, Alanen K, Nurmi M, Nees M, Härkönen P.
    Int J Cancer; 2016 Jul 01; 139(1):140-52. PubMed ID: 26891277
    [Abstract] [Full Text] [Related]

  • 6. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    Georgescu C, Corbin JM, Thibivilliers S, Webb ZD, Zhao YD, Koster J, Fung KM, Asch AS, Wren JD, Ruiz-Echevarría MJ.
    BMC Cancer; 2019 May 06; 19(1):423. PubMed ID: 31060542
    [Abstract] [Full Text] [Related]

  • 7. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
    Li T, Gui Y, Yuan T, Liao G, Bian C, Jiang Q, Huang S, Liu B, Wu D.
    BJU Int; 2012 Dec 06; 110(11 Pt C):E1125-30. PubMed ID: 22672360
    [Abstract] [Full Text] [Related]

  • 8. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
    Chen WY, Hua KT, Lee WJ, Lin YW, Liu YN, Chen CL, Wen YC, Chien MH.
    Int J Mol Sci; 2016 Jul 23; 17(8):. PubMed ID: 27455254
    [Abstract] [Full Text] [Related]

  • 9. Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.
    Zeng X, Hu Z, Wang Z, Tao J, Lu T, Yang C, Lee B, Ye Z.
    Prostate Cancer Prostatic Dis; 2014 Jun 23; 17(2):119-25. PubMed ID: 24418912
    [Abstract] [Full Text] [Related]

  • 10. Elevated UHRF1 expression contributes to poor prognosis by promoting cell proliferation and metastasis in hepatocellular carcinoma.
    Liu X, Ou H, Xiang L, Li X, Huang Y, Yang D.
    Oncotarget; 2017 Feb 07; 8(6):10510-10522. PubMed ID: 28060737
    [Abstract] [Full Text] [Related]

  • 11. Overexpression of certain transient receptor potential and Orai channels in prostate cancer is associated with decreased risk of systemic recurrence after radical prostatectomy.
    Perrouin-Verbe MA, Schoentgen N, Talagas M, Garlantezec R, Uguen A, Doucet L, Rosec S, Marcorelles P, Potier-Cartereau M, Vandier C, Ferec C, Fromont G, Fournier G, Valeri A, Mignen O.
    Prostate; 2019 Dec 07; 79(16):1793-1804. PubMed ID: 31475744
    [Abstract] [Full Text] [Related]

  • 12. Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential.
    Ruela-de-Sousa RR, Hoekstra E, Hoogland AM, Souza Queiroz KC, Peppelenbosch MP, Stubbs AP, Pelizzaro-Rocha K, van Leenders GJLH, Jenster G, Aoyama H, Ferreira CV, Fuhler GM.
    Eur Urol; 2016 Apr 07; 69(4):710-719. PubMed ID: 26159288
    [Abstract] [Full Text] [Related]

  • 13. Decreased TSPAN1 promotes prostate cancer progression and is a marker for early biochemical recurrence after radical prostatectomy.
    Xu F, Gao Y, Wang Y, Pan J, Sha J, Shao X, Kang X, Qin J, You MJ, Huang Y, Dong B, Xue W.
    Oncotarget; 2016 Sep 27; 7(39):63294-63305. PubMed ID: 27556508
    [Abstract] [Full Text] [Related]

  • 14. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X, Wang Y, Ning Y.
    Urol Oncol; 2017 Mar 27; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [Abstract] [Full Text] [Related]

  • 15. Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.
    Pashaei E, Pashaei E, Ahmady M, Ozen M, Aydin N.
    PLoS One; 2017 Mar 27; 12(6):e0179543. PubMed ID: 28651018
    [Abstract] [Full Text] [Related]

  • 16. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
    Wan S, Xi M, Zhao HB, Hua W, Liu YL, Zhou YL, Zhuo YJ, Liu ZZ, Cai ZD, Wan YP, Zhong WD.
    Pathol Res Pract; 2019 Aug 27; 215(8):152464. PubMed ID: 31176575
    [Abstract] [Full Text] [Related]

  • 17. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
    Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G.
    Am J Surg Pathol; 2004 Jul 27; 28(7):928-34. PubMed ID: 15223964
    [Abstract] [Full Text] [Related]

  • 18. CD147 expression predicts biochemical recurrence after prostatectomy independent of histologic and pathologic features.
    Bauman TM, Ewald JA, Huang W, Ricke WA.
    BMC Cancer; 2015 Jul 25; 15():549. PubMed ID: 26209327
    [Abstract] [Full Text] [Related]

  • 19. Human antigen R is positively associated with malignant aggressiveness via upregulation of cell proliferation, migration, and vascular endothelial growth factors and cyclooxygenase-2 in prostate cancer.
    Mitsunari K, Miyata Y, Asai A, Matsuo T, Shida Y, Hakariya T, Sakai H.
    Transl Res; 2016 Sep 25; 175():116-28. PubMed ID: 27140699
    [Abstract] [Full Text] [Related]

  • 20. Tumor suppressor function of PGP9.5 is associated with epigenetic regulation in prostate cancer--novel predictor of biochemical recurrence after radical surgery.
    Mitsui Y, Shiina H, Hiraki M, Arichi N, Hiraoka T, Sumura M, Honda S, Yasumoto H, Igawa M.
    Cancer Epidemiol Biomarkers Prev; 2012 Mar 25; 21(3):487-96. PubMed ID: 22246902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.